{"disease":{"id":"atrial-fibrillation-af","name":"atrial fibrillation af"},"drugs":{"marketed":[{"drug_id":"flecainide","indication_name":"Paroxysmal Atrial Fibrillation/Flutter (PAF)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"flecainide-acetate","indication_name":"Paroxysmal Atrial Fibrillation/Flutter (PAF)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLECAINIDE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":17,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06881797","title":"Unrecognised Comorbidity Detection in Hospitalised Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4500000,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT06802965","title":"Shanghai Atrial Fibrillation Registry","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":400000,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT06987825","title":"Chinese Atrial Fibrillation Registry","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT05022758","title":"A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin","phase":"","overall_status":"COMPLETED","enrollment_count":45000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06772207","title":"Cardiac Rehabilitation Needs Among Individuals With Atrial Fibrillation","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"Odense University Hospital","has_results":false},{"nct_id":"NCT07149688","title":"Village-Based Management of Chronic Cardiovascular Disease in Qu Jiang Elderly Population Registry: The BOUQUET Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT06931288","title":"Electronic Blood Pressure Monitor for Atrial Fibrillation Detection","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT06842147","title":"Effectiveness of Artificial IntelliGence-Driven Single-LEad Long-TerM Electrocardiograms MonItoring in Detecting New-Diagnosed Atrial FIbrillation","phase":"NA","overall_status":"RECRUITING","enrollment_count":15360,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT06763549","title":"COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":15000,"lead_sponsor_name":"Peerbridge Health, Inc","has_results":false},{"nct_id":"NCT06847932","title":"Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development","phase":"NA","overall_status":"RECRUITING","enrollment_count":14726,"lead_sponsor_name":"National Defense Medical Center, Taiwan","has_results":false},{"nct_id":"NCT05027061","title":"A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":11776,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06686940","title":"Photoplethysmography (PPG) Algorithm With Smartwatch in Evaluation of Atrial Fibrillation Burden","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT06842160","title":"Photoplethysmography (PPG) Algorithm with Smartwatch in Evaluation of Atrial Fibrillation Burden After Catheter Ablation","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT06871228","title":"Discontinuation of Anticoagulation With Intensive Rhythm Monitoring in Post-ablation Patients With Atrial Fibrillation","phase":"NA","overall_status":"RECRUITING","enrollment_count":4100,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT07343895","title":"Population-based Atrial Fibrillation Screening in Individuals With NT-proBNP Above Median in the Tromsø Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"University Hospital of North Norway","has_results":false},{"nct_id":"NCT03234114","title":"Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":3746,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT07309913","title":"China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3459,"lead_sponsor_name":"Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT03310125","title":"Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3209,"lead_sponsor_name":"Population Health Research Institute","has_results":false},{"nct_id":"NCT05955365","title":"Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":3010,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT07345403","title":"GENECARD - the Use of Genetic, Epigenetic, Metabolomic, Proteomic and Microbiotic Markers, Image and Voice Biomarker Analyses, and Pre- and Intraoperative Clinical Data - to Predict Early Complications After Cardiac Surgery.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Medical University of Gdansk","has_results":false},{"nct_id":"NCT07278089","title":"AF Screening in Patients With Abnormal Echocardiographic Parameters","phase":"NA","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Tze-Fan Chao","has_results":false},{"nct_id":"NCT06583395","title":"Quest to Analyze One Thousand Humans Meditating","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"Tobias Moeller-Bertram","has_results":false},{"nct_id":"NCT07518446","title":"Somatic Health Screening for Adults in Outpatient Psychiatric Care in Denmark (SomaScreen)","phase":"NA","overall_status":"RECRUITING","enrollment_count":2800,"lead_sponsor_name":"Amager Hospital","has_results":false},{"nct_id":"NCT07430956","title":"Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":2628,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT06648837","title":"Microvisk Continuous Blood Donation Study","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Microvisk Technologies Ltd","has_results":false},{"nct_id":"NCT02513316","title":"Clinical Relevance of Microbleeds In Stroke","phase":"","overall_status":"COMPLETED","enrollment_count":2490,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT06779695","title":"Prediction of Systemic Thromboembolism and Bleeding in Atrial Fibrillation Patients With Factor Xa Inhibitor (Apixaban, Rivaroxaban) by Echocardiographic Parameters: Prospective Observational Study (AF-ECHO Study)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Korea University Anam Hospital","has_results":false},{"nct_id":"NCT07085650","title":"The Multi-center Study of Comprehensive Atrial Fibrillation Regurgitation and Recurrent Events Evaluation","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"First Hospital of China Medical University","has_results":false},{"nct_id":"NCT05712200","title":"Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1900,"lead_sponsor_name":"Anthos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06844227","title":"Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)","phase":"","overall_status":"RECRUITING","enrollment_count":1780,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT06611995","title":"Prediction of Stroke Risk in Patients with Atrial Fibrillation Based on Chest CT Images","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT04755283","title":"Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1287,"lead_sponsor_name":"Anthos Therapeutics, Inc.","has_results":true},{"nct_id":"NCT06775028","title":"Integrated Approach in Frail Older People with Atrial Fibrillation","phase":"NA","overall_status":"RECRUITING","enrollment_count":1250,"lead_sponsor_name":"Heart Care Foundation","has_results":false},{"nct_id":"NCT06505798","title":"Cryoballoon/Radiofrequency/Pulsed Field Ablation of Atrial Fibrillation Versus Medical Treatment for Heart","phase":"NA","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT07175428","title":"Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT07518966","title":"Association Between Early Recurrence and Long-Term Recurrence After Pulsed Field Ablation for Atrial Fibrillation: Prospective Real-World Evidence From China","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT07238452","title":"Optimising Pacing Therapy, Integrated Medical Therapy, and Catheter AbLation for Atrial Fibrillation in Heart Failure Trial","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":1056,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT07196176","title":"Electrophysiological Registry Duesseldorf","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Heinrich-Heine University, Duesseldorf","has_results":false},{"nct_id":"NCT06995391","title":"Digitally Rendered Interventions And Knowledge To Limit Ethanol-Associated Atrial Fibrillation Severity","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT07242326","title":"SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye)","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1000,"lead_sponsor_name":"Kotyora Family Medicine Health Management and Education Association","has_results":false},{"nct_id":"NCT07497893","title":"FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Ewha Womans University Mokdong Hospital","has_results":false},{"nct_id":"NCT07438054","title":"PRO-AF 52: Monthly Primary-Care 12-Lead ECG Screening for Incident Atrial Fibrillation in Adults Aged ≥65 Years","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1000,"lead_sponsor_name":"Kotyora Family Medicine Health Management and Education Association","has_results":false},{"nct_id":"NCT07441759","title":"throMboembolic Risk Associated To High atrIal Fibrillation riSk","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina","has_results":false},{"nct_id":"NCT06598995","title":"Myocardial Bridging in Obstructive Hypertrophic Cardiomyopathy","phase":"","overall_status":"COMPLETED","enrollment_count":968,"lead_sponsor_name":"Chinese Academy of Medical Sciences, Fuwai Hospital","has_results":false},{"nct_id":"NCT07380932","title":"Catheter Ablation for AF in Patients With Severe Mitral Regurgitation After Successful Transcatheter Mitral-Valve Repair","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":956,"lead_sponsor_name":"Atrial Fibrillation Network","has_results":false},{"nct_id":"NCT06618417","title":"Evaluating the Impact of Home-Based Sleep Apnea Diagnostic on Well-Being, Health Behavior, and AF Load in Patients with Atrial Fibrillation Using a Decentralized Platform","phase":"NA","overall_status":"RECRUITING","enrollment_count":936,"lead_sponsor_name":"Herlev and Gentofte Hospital","has_results":false},{"nct_id":"NCT03746301","title":"Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation","phase":"","overall_status":"COMPLETED","enrollment_count":924,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06957366","title":"Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure","phase":"NA","overall_status":"RECRUITING","enrollment_count":920,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT04218266","title":"Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":755,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT01598051","title":"Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":741,"lead_sponsor_name":"Bayer","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}